Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort

Table 3 Models with different combinations of variables

	Model	10-fold cross-validation in AD continuum	Validation in the SVCI group
Model 1	Age	0.506 (0.407, 0.512)	0.643 (0.485, 0.8)
Model 2	APOE4	0.723 (0.614, 0.717)	0.59 (0.475, 0.705)
Model 3	Age + APOE4	0.727 (0.652, 0.751)	0.699 (0.558, 0.839)
Model 4	Aβ42/Aβ40	0.818 (0.76, 0.847)	0.823 (0.702, 0.944)
Model 5	APOE4 + Aβ42/Aβ40	0.858 (0.799, 0.876)	0.775 (0.646, 0.905)
Model 6	Age + APOE4 + Aβ42/Aβ40	0.855 (0.797, 0.875)	0.777 (0.648, 0.905)
Model 7	Age + APOE4 + Aβ42/Aβ40 + diagnosis	0.916 (0.877, 0.934)	NA

Values are presented as AUC (95% confidence interval for AUC). Except for model 2 vs. model 3 (p = 0.661) and model 5 vs. model 6 (p = 0.791), all two individual models showed statistically different AUC values (all p < 0.05)
AUC area under the receiver operating characteristic curve

ISSN: 1758-9193